/ 2 items

#AARD↓

AARD/ 12/23/2025 · 7:44 AM

Oppenheimer Starts Coverage on Aardvark Therapeutics with Strong Rating

Oppenheimer analyst gives Aardvark Therapeutics an Outperform rating with $35 price target, highlighting rare and common obesity drug programs and a key Phase 3 trial.

AARD/ 12/02/2025 · 4:40 PM

Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating

Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.